((自动化翻译由路透提供,请见免责声明 ))
路透9月24日 - 安进公司(Amgen )周二称,其实验药物rocatinlimab在一项后期研究中达到了主要目标,该研究测试该药物作为特应性皮炎的一种炎症性皮肤病的治疗方法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.